Review

. 2015 Dec;96(3):385-98.

doi: 10.1016/j.critrevonc.2015.08.021. Epub 2015 Aug 28.

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Matteo S Carlino¹, Georgina V Long², Richard F Kefford³, Helen Rizos⁴

Affiliations

¹ Departments of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; The Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. Electronic address: matteo.carlino@sydney.edu.au.
² Melanoma Institute Australia, Sydney, New South Wales, Australia; The Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; The Mater Hospital, North Sydney, New South Wales, Australia.
³ Departments of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.
⁴ Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.

PMID: 26358420
DOI: 10.1016/j.critrevonc.2015.08.021

Review

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Matteo S Carlino et al. Crit Rev Oncol Hematol. 2015 Dec.

. 2015 Dec;96(3):385-98.

doi: 10.1016/j.critrevonc.2015.08.021. Epub 2015 Aug 28.

Authors

Matteo S Carlino¹, Georgina V Long², Richard F Kefford³, Helen Rizos⁴

Affiliations

¹ Departments of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; The Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia. Electronic address: matteo.carlino@sydney.edu.au.
² Melanoma Institute Australia, Sydney, New South Wales, Australia; The Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia; The Mater Hospital, North Sydney, New South Wales, Australia.
³ Departments of Medical Oncology, Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia; Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.
⁴ Centre for Cancer Research, Westmead Millennium Institute, Westmead, New South Wales, Australia; Melanoma Institute Australia, Sydney, New South Wales, Australia; Faculty of Medicine and Health Science, Macquarie University, New South Wales, Australia.

PMID: 26358420
DOI: 10.1016/j.critrevonc.2015.08.021

Abstract

BRAF and MEK inhibitors, alone or in combination, are highly active in the 40% of patients with BRAF mutant metastatic melanoma. Despite this activity resistance often develops in patients treated with these agents. This review summarises the biology of the mitogen activated protein kinase (MAPK) pathway, with particular reference to the effects of BRAF and MEK inhibitors in BRAF mutant melanoma. The clinical and molecular predictors of response and mechanisms of resistance are discussed in detail along with the biological rationale and evidence for future treatment strategies in both MAPK inhibitor naïve and resistant BRAF mutant melanoma.

Keywords: BRAF inhibitors; BRAF mutations; MEK inhibitors; Melanoma; Resistance; Targeted therapy.

PubMed Disclaimer

Cited by

The Impact of Ultraviolet Radiation on the Aetiology and Development of Uveal Melanoma.
Chalada M, Ramlogan-Steel CA, Dhungel BP, Layton CJ, Steel JC. Chalada M, et al. Cancers (Basel). 2021 Apr 3;13(7):1700. doi: 10.3390/cancers13071700. Cancers (Basel). 2021. PMID: 33916693 Free PMC article. Review.
POT1 and Damage Response Malfunction Trigger Acquisition of Somatic Activating Mutations in the VEGF Pathway in Cardiac Angiosarcomas.
Calvete O, Garcia-Pavia P, Domínguez F, Mosteiro L, Pérez-Cabornero L, Cantalapiedra D, Zorio E, Ramón Y Cajal T, Crespo-Leiro MG, Teulé Á, Lázaro C, Morente MM, Urioste M, Benitez J. Calvete O, et al. J Am Heart Assoc. 2019 Sep 17;8(18):e012875. doi: 10.1161/JAHA.119.012875. Epub 2019 Sep 12. J Am Heart Assoc. 2019. PMID: 31510873 Free PMC article.
Cutaneous Melanoma: A Review of Multifactorial Pathogenesis, Immunohistochemistry, and Emerging Biomarkers for Early Detection and Management.
Gosman LM, Țăpoi DA, Costache M. Gosman LM, et al. Int J Mol Sci. 2023 Nov 1;24(21):15881. doi: 10.3390/ijms242115881. Int J Mol Sci. 2023. PMID: 37958863 Free PMC article. Review.
BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis.
Garutti M, Bergnach M, Polesel J, Palmero L, Pizzichetta MA, Puglisi F. Garutti M, et al. Cancers (Basel). 2022 Dec 26;15(1):141. doi: 10.3390/cancers15010141. Cancers (Basel). 2022. PMID: 36612138 Free PMC article.
MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling.
Shen Q, Han Y, Wu K, He Y, Jiang X, Liu P, Xia C, Xiong Q, Liu R, Chen Q, Zhang Y, Zhao S, Yang C, Chen Y. Shen Q, et al. Signal Transduct Target Ther. 2022 May 4;7(1):147. doi: 10.1038/s41392-022-00945-9. Signal Transduct Target Ther. 2022. PMID: 35504869 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Affiliations

Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Research Materials